Efficacy and tolerability of aripiprazole in adolescents with schizophrenia

被引：0
|
作者：
Forbes, A. [1 ]
Nyilas, M. [1 ]
Loze, J. [2 ]
Werner, C. [3 ]
Johnson, B. [1 ]
Owen, R. [4 ]
Todorov, S. [5 ]
Carson, W. H. [1 ]
机构：
[1] Otsuka Pharmaceut Dev & Commercializat, Princeton, NJ USA
[2] Otsuka Pharmaceut France SAS, Rueil Malmaison, France
[3] Otsuka Frankfurt Res Inst, Frankfurt, Germany
[4] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[5] Multiprofiled Hosp Act Treatment, Psychiat Clin 1, Varna, Bulgaria
来源：
EUROPEAN PSYCHIATRY | 2008年 / 23卷
关键词：
D O I：
10.1016/j.eurpsy.2008.01.786
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [21] Meta-analysis of the safety and tolerability profile of aripiprazole in schizophrenia
    McQuade, R
    Saha, A
    Kaplita, S
    Archibald, D
    Iwamoto, T
    Stock, E
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S290 - S290
  • [22] Quetiapine: efficacy and tolerability in schizophrenia
    Kasper, S
    Tauscher, J
    Heiden, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 : 405 - 413
  • [23] Efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder
    Kujawa, M
    Stringfellow, J
    Hardy, S
    Ali, M
    Iwamoto, T
    Lam, S
    Marcus, R
    Stock, E
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 156 - 156
  • [24] Aripiprazole/SulpiridePoor tolerability and lack of efficacy : case report
    Reactions Weekly, 2024, 2020 (1) : 75 - 75
  • [25] Clinical effects and tolerability of aripiprazole in children and adolescents with psychiatric disorders
    Ramos-Rios, R.
    Gago-Ageitos, A. M.
    Vidal-Millares, M.
    Mazaira-Castro, J. A.
    Dominguez-Santos, M. D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S691 - S691
  • [26] Efficacy and tolerability of long-term (up to 5 years) open-label treatment with aripiprazole in schizophrenia
    Carson, W
    Ali, M
    Saha, A
    McQuade, R
    Owen, R
    Stock, E
    Yamamoto, Y
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S510 - S510
  • [27] Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
    Oya, Kazuto
    Kishi, Taro
    Iwata, Nakao
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 2299 - 2307
  • [28] A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder
    Kim, Chang Yoon
    Chung, Seockhoon
    Lee, Joon-Noh
    Kwon, Jun Soo
    Kim, Do Hoon
    Kim, Chul Eung
    Jeong, Bumseok
    Jeon, Yang-Whan
    Lee, Min-Soo
    Jun, Tae-Youn
    Jung, Hee-Yeon
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (04) : 181 - 188
  • [29] Efficacy and safety of aripiprazole and haloperidol in patients with schizophrenia
    Sulejmanpasic-Arslanagic, G.
    Kapetanovic, D.
    Srebrenka, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S490 - S491
  • [30] Meta-analysis of the efficacy of aripiprazole in schizophrenia
    Carson, WH
    Saha, AR
    Stringfellow, JC
    Archibald, DG
    Marcus, R
    Kujawa, MJ
    Iwamoto, I
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 276 - 276
12345